That’s Nice and Haig Barrett Launch Consulting Service
The two companies will combine life-sciences marketing and a consulting firm to create a life sciences-centered consulting service.
That’s Nice LLC, a research-focused strategic marketing agency for the life-science markets, and Haig Barrett, management consultants based in Los Angeles, announced at CPhI Worldwide 2015 the launch of Nice Consulting, a service designed to offer strategic and specialized consulting tailored to the needs of companies in life sciences. The companies hope that Nice Consulting will help life-science companies manage the rapid growth of the life-sciences market with a single, knowledgeable partner “to guide them in pursuing and achieving their goals through effective positioning, branding, and marketing.”
“Life Sciences is fast paced and driven by innovation. Communicating the value in an often rapidly-evolving product portfolio is key to success,” said Nigel Walker, Managing Director of That’s Nice, in a press release.
Haig Armaghanian, CEO and founder of Haig Barrett, said, “Life-science companies need creative insight and strategic support in a range of areas. Our integrated services support growth aspirations pursued through mergers and acquisitions, market expansion, or leveraging of the existing customer base through customer experience enhancement and sales enablement.”
Source: That’s Nice
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
